Thermo Fisher, Sym­phogen to de­velop work­flows

BioSpectrum (India) - - SUPPLIER NEWS -

Thermo Fisher Sci­en­tific, the world leader in serv­ing sci­ence, and Sym­phogen, a clin­i­cal-stage an­ti­body on­col­ogy-fo­cused com­pany, have en­tered into a two-year col­lab­o­ra­tive part­ner­ship to de­liver val­i­dated, plat­form work­flows for sim­pli­fied char­ac­ter­i­za­tion and qual­ity mon­i­tor­ing of com­plex ther­a­peu­tic pro­teins. Build­ing on a decade-long re­la­tion­ship, the new col­lab­o­ra­tion will de­velop pro­tein anal­y­sis work­flows to ac­cel­er­ate drug de­vel­op­ment for bio­phar­ma­ceu­ti­cal in­no­va­tors, biosim­i­lar man­u­fac­tur­ers, con­tract re­search or­ga­ni­za­tions, and con­tract de­vel­op­ment and man­u­fac­tur­ing or­ga­ni­za­tions. Sym­phogen will use the Thermo Sci­en­tific Q Ex­ac­tive Plus Or­bi­trap liq­uid chro­matog­ra­phy-tan­dem mass spec­trom­e­try (LC-MS/MS) sys­tem with Bio­Pharma Op­tion to cre­ate, test and val­i­date plat­form work­flows for in­tact and na­tive mass anal­y­sis of ther­a­peu­tic mon­o­clonal an­ti­body (mAb) mix­tures. Ad­di­tional fo­cus will be placed on the de­vel­op­ment of au­to­mated multi-at­tribute method (MAM) work­flows for mon­i­tor­ing crit­i­cal qual­ity at­tributes of pro­teins using high-res­o­lu­tion ac­cu­ratemass mass spec­trom­e­try in a qual­ity con­trol en­vi­ron­ment.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.